Clinical trials: Migraine
Migraine
Efficacy of Erenumab on Functional Impact of Migraine
The purpose of this study is to assess the efficacy of erenumab on functional impact due to Migraine in adults.
- Trial name
- NCT04465357
- Testing
- Erenumab-Aooe 140 MG/ML [Aimovig]
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Merle Diamond
Headache
Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department
This study will randomly assign emergency department patients seeking treatment for a headache to one of three groups. The first group will receive standard emergency care as determined by the treating physician, the second group…
- Trial name
- NCT00856232
- Testing
- Medical Air, Oxygen
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acute Migraine
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
- Trial name
- NCT04153409
- Testing
- LAT8881
- Where
- 3 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Lateral Pharma Pty Ltd
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Benign Headache
Bupivacaine for Benign Headache in the ED
Headache is a common chief complaint of patients presenting to the emergency department (ED), accounting for approximately 3 million ED visits per year.
- Trial name
- NCT01785459
- Testing
- 0.5% bupivacaine, Standard Care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraines
A Study of LY2951742 in Healthy Volunteers
To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects
- Trial name
- NCT01337596
- Testing
- LY2951742
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Headache Migraine Chronic
Spectacle Tints and Thin-Films for Migraine
Nearly all migraine sufferers report sensitivity to light during a headache and a significant proportion of sufferers report light sensitivity between attacks. Light is also a common trigger for migraine headaches.
- Trial name
- NCT02720211
- Testing
- Gray tinted spectacle lenses, Thin-Film spectacle lenses
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Migraine With Aura, Patent Foramen Ovale
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
The purpose of the study is to compare the rate of comorbidities associated with migraine aura (MA) between persons who have a large circulatory right-to-left shunt (RLS) and those who do not have RLS.
- Trial name
- CAMP (NCT01257880)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Swedish Medical Center
Migraine
Two Rizatriptan Prescribing Portions for Treatment of Migraine
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT…
- Trial name
- NCT00397254
- Testing
- rizatriptan
- Where
- 10 sites in United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Clinvest
Migraine
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity.
- Trial name
- ADAM (NCT03282227)
- Testing
- M207 Microneedle System
- Where
- 31 sites in United States
- Volunteers
- 342 people
- Sponsor
- Zosano Pharma Corporation
Migraine, Patent Foramen Ovale
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
- Conditions
- Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
- Trial name
- RELIEF (NCT04100135)
- Testing
- Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel)
- Where
- 15 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.
- Trial name
- NCT00516737
- Testing
- Comparator: rizatriptan benzoate
- Volunteers
- 207 people
- Sponsor
- Organon and Co
Migraine, Tension-type Headache
Comparing Naproxen to Sumatriptan for Emergency Headache Patients
2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment.
- Conditions
- Migraine, Tension-type Headache, Primary Headache Disorder
- Trial name
- HEDNet2 (NCT00449787)
- Testing
- Sumatriptan 100 mg, Naproxen
- Where
- 2 sites in United States
- Volunteers
- 401 people
- Sponsor
- Montefiore Medical Center
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine Headache
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
- Trial name
- NCT02163993
- Testing
- Galcanezumab
- Where
- 40 sites in United States
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company